PHVS | Pharvaris N.V. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	18.81 - 20.55
52 Week Range	15.37 - 33.00
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	51,494
Average Volume	103,753
Shares Outstanding	54,007,700
Market Cap	1,107,157,850
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-02-05

Valuation
Profitability
Growth
Health
P/E Ratio	-7.48
Forward P/E Ratio	N/A
EPS	-2.74
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	83
Country	Netherlands
Website	PHVS

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

PHVS's peers: ACIU, ANTX, PMCB, CADL, GHRS, GNTA, HCWB, IOBT, MGNX, MNOV, MNPR, MOLN, OLMA, OMGA, ORIC, PMVP, ELYM, PEPG, MLYS, GLUE, DSGN, HOWL, IKNA, STOK, TYRA, ANEB, JANX, RZLT, PRAX, PRLD, PSTX, RANI, RAPT, RLYB, SEER, SLGL, TARS, THTX, TRDA, VIGL, HLVX, QNCX, VANI, ZVRA

*Chart delayed

Analyzing fundamentals for PHVS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see PHVS Fundamentals page.

Watching at PHVS technicals we can see that long-term trend is bearish, while middle-term trend is bullish, but short-term trend is bearish. More technicals details can be found on PHVS Technicals page.